Cristcot Appoints Rayna Herman as President of its Hydrocortisone Acetate Commercial Division

We are pleased to welcome Rayna to the Cristcot team. She is an effective cross-functional leader with a proven track record building and scaling commercial operations, including integration to the ...

Cristcot to Present Oral Abstract at 2026 Digestive Disease Week (DDW)

Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company will present its abstract evaluating the impact of ...
Yahoo Finance

Cristcot Announces FDA Acceptance of NDA for Next-Generation Hydrocortisone Acetate (ngHCA) for Treatment of Ulcerative Colitis (UC) of the Rectum

AUSTIN, Texas, April 21, 2026 (GLOBE NEWSWIRE)-- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the U.S. Food and ...
PharmiWeb

Cristcot Appoints Jenny Gizzi as Chief Administrative Officer

CONCORD, Mass., May 19, 2025 – Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, today announced the appointment of Jenny Gizzi as Chief ...
Mena FN

Cristcot Highlights Engagement With GI Community At 2025 GI Reconnect Annual Meeting

CONCORD, Mass., June 24, 2025 /PRNewswire/ -- Cristcot , a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, participated in the 5 th annual GI ...
Medindia

Cristcot to Present Data on Novel Ulcerative Colitis Treatment at the American College of Gastroenterology 2025 Annual Meeting

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical ...
Hosted on MSN

New hope for ulcerative colitis relief

A next-generation hydrocortisone acetate suppository for rectal ulcerative colitis has shown strong Phase 3 results, achieving rapid symptom relief and remission in many patients. Delivered via the ...
KOIN 6

Cristcot Announces Positive Phase 3 Results for Novel Hydrocortisone Acetate Suppository Administered with the Sephure® Suppository Applicator for the Treatment of Ulcerative ...

Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...
Mena FN

Cristcot Announces FDA Acceptance Of NDA For Next-Generation Hydrocortisone Acetate (Nghca) For Treatment Of Ulcerative Colitis (UC) Of The Rectum

-- Prescription Drug User Fee Act (PDUFA) target date of October 2026 -- -- Submission supported by CESSA Phase 3 trial results demonstrating statistically significant rates of clinical remission in ...
manilatimes

Cristcot to Present Oral Abstract at 2026 Digestive Disease Week (DDW)

Oral presentation on the impact of concomitant steroid use in ulcerative colitis (UC) scheduled for May 5, 2026, at 9:30am CDT AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE)-- Cristcot, a ...
MarketWatch

Cristcot Announces Positive Phase 3 Results for Novel Hydrocortisone Acetate Suppository Administered with the Sephure(R) Suppository Applicator for the Treatment of Ulcerative ...

Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...